Beam Therapeutics Inc. (BEAM)

Market Cap	1.89B
Revenue (ttm)	377.71M
Net Income (ttm)	-132.53M
Shares Out	81.66M
EPS (ttm)	-1.72
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,023,621
Open	23.64
Previous Close	22.72
Day's Range	22.94 - 24.60
52-Week Range	16.95 - 49.50
Beta	1.77
Analysts	Buy
Price Target	43.10 (+86.34%)
Earnings Date	May 17, 2024

About BEAM

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301,...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 6, 2020
• Employees: 507
• Stock Exchange: NASDAQ
• Ticker Symbol: BEAM

Financial Performance

In 2023, BEAM's revenue was $377.71 million, an increase of 520.01% compared to the previous year's $60.92 million. Losses were -$132.53 million, -54.16% less than in 2022.

Analyst Forecast

According to 10 analysts, the average rating for BEAM stock is "Buy." The 12-month stock price forecast is $43.1, which is an increase of 86.34% from the latest price.

Price Target

$43.1

(86.34% upside)

Analyst Consensus: Buy